Merck is strengthening its semiconductor manufacturing footprint in South Korea with a new molybdenum production facility designed to accelerate next-generation chip development, secure local supplies ...
A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma ...
Investor's Business Daily on MSN
How Halozyme, up nearly 90% this year, is rivaling Merck and hitting new highs
Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with ...
When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each ...
Merck's Courtney Ronaldo discusses the strategy behind the company's new oncology campaign, its multichannel presence at ESMO ...
1d
Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...
Merck stock looks fairly valued as Keytruda risks, slower EPS growth, and debt weigh on upside. Click here to read an ...
Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...
Moderna and Merck's personalized mRNA vaccine, combined with Keytruda, reduces melanoma recurrence or death risk in Phase 3 ...
Moderna and Merck said on Thursday that their mRNA cancer vaccine when combined with Merck's widely used immunotherapy cut the risk of melanoma death or recurrence by 42% in a large trial, potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results